The CHARISMA trial and the REACH registry outcomes [1]

Journal of the National Medical Association

Volumn 98, Issue 10, 2006, Pages 1713-

  Faxon, David P ^a   Nesto, Richard W ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; STATIN;

ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART INFARCTION; HUMAN; LETTER; PRIORITY JOURNAL; STROKE; THROMBOSIS; TREATMENT OUTCOME;

CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; HUMANS; INCIDENCE; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 33750598745     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Faxon DP, Nesto RW. Antiplatelet therapy in populations at high risk of atherothrombosis. J Natl Med Assoc. 2006;98:711-721.
2. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.
3. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-189.